chronic kidney disease with type 2 diabetes mellitus
Conditions
Interventions
Test group:finerenone in combination with canagliflozin
Control group:finerenone
Sponsors
The Third Hospital of Mianyang, Sichuan Mental Health Center
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: ?Definite diagnosis of chronic kidney disease with type 2 diabetes mellitus; ?Age = 18 years; ? Receiving maximum tolerated dose of angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ? urinary albumin-to-creatinine >30mg/g, 30 <estimated glomerular filtration rate<90ml/min/1.73m2; ? serum potassium = 5.0 mmol/L.
Exclusion criteria
Exclusion criteria: ? type 1 diabetes mellitus; ? serum potassium >5.0mmol/l at screening; ? those who do not wish to participate in the clinical trial; ? severe liver injury (child-pugh C); ? pregnant or breastfeeding women; ? addison’s disease; ? active malignant tumours.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urinary albumin-to-creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| estimated glomerular filtration rate;creatinine;left ventricular ejection fration;left ventricle mass index;cardiovascular events; | — |
Countries
China
Contacts
Public ContactMeijiang
The Third Hospital of Mianyang, Sichuan Mental Health Center
Outcome results
None listed